Cannabinerol and NSC-34 transcriptomic analysis: is the dose who makes differentiation?

Cannabis Sativa proved to be a source of several phytocompounds able to helphumankind facing different diseases, at least to ameliorate the general conditions and control some unpleasant effects of disease. Some cannabinoids, however, proved to be more than a palliative. Using NSC-34 cell line, we tested the barely unknown phytocompound named Cannabinerol at different doses, in order to understand its unique characteristics and the ones shared with other cannabinoids. The transcriptomic analysis suggest a possible ongoing neuronal differentiation, principally due to the activation of CB1, to which the phosphorylation of Akt followed, especially between 20 and 7.5 uM. The increase of Neurod1 and Map2 genes at 7.5 uM, accompanied with a decrease of Vim, as well as the increase of Syp in all the other doses, point toward the initiation of differentiation signals. Our preliminary results indicates CBNR as a promised candidate to be added in the list of cannabinoids with neurogenesis-enhancer properties, even though more studies are needed to confirm this first insight.